The
customized peptide synthesis market is projected to generate a revenue of
$390.0 million by 2024 as per a recent P&S Intelligence study. The market
is being progressively driven by technological innovations, growing burden of
cancer and infectious diseases, increasing investments and funding for
protein-based research, and rising research activities in synthetic biology.
There are two main types of products available in the
customized peptide synthesis market: reagents and equipment. Among the two, the
reagents category is expected to witness the faster growth during the forecast
period, registering a CAGR of 6.8%. The reason for such a growth of the domain would
be the heavy usage of a wide variety of reagents, including additives, substrates,
precipitation agents, buffers, and others.
 |
| To Learn More About this report@ http://bit.ly/3cycoSu |
Now talking about the application segment, commercial application is
expected to be the fastest growing in the customized peptide synthesis market
during the forecast period, registering a CAGR of 6.9%. The inclusion of
modified amino acids and recent advancements in chemical peptide synthesis have
expanded the commercial potential of customized peptides. Moving further to the
technology segment, the solid-phase
peptide synthesis (SPPS) technology is projected
to gain the most ground during 2019–2024, advancing at a CAGR of 6.9%.
New research findings would give the customized peptide
synthesis market players a great opportunity to discover new drugs derived from
peptides. For instance, in 2017, the anorectic effect of PYY3–36, which is a
fragment of peptide YY, in rats was reported by scientists at Takeda
Pharmaceuticals Company Ltd. Further, China Medical System Holdings Limited
developed XinHouSu, an injectable recombinant human brain natriuretic peptide, to
treat acute heart failure. XinHouSu, which is currently available only in
China, collected $62.3 million in revenue in 2017, which amounted to an 18.9% growth
from 2016.
